Lansoprazol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lansoprazol

What is Lansoprazole?

Lansoprazole is a medication that belongs to a class of drugs known as proton pump inhibitors (PPIs). It is primarily used to manage conditions related to the overproduction of stomach acid. By targeting the acid-producing pumps in the lining of the stomach, lansoprazole reduces the total amount of acid secreted into the digestive system.

Mechanism of Action

The medication works by inhibiting the hydrogen-potassium ATPase enzyme system, commonly referred to as the "proton pump." This system is the final step in the acid secretion process. By blocking these pumps, lansoprazole provides a sustained reduction in gastric acidity, which allows the esophagus and stomach lining to heal from acid-related damage.

Primary Uses

Lansoprazole is commonly utilized in the management of several gastrointestinal conditions, including:

  • Gastroesophageal Reflux Disease (GERD): A condition where stomach acid frequently flows back into the tube connecting the mouth and stomach, causing irritation.
  • Erosive Esophagitis: Inflammation and damage to the lining of the esophagus resulting from chronic acid exposure.
  • Gastric and Duodenal Ulcers: The treatment and prevention of sores that develop on the lining of the stomach or the upper part of the small intestine.
  • Zollinger-Ellison Syndrome: A rare condition characterized by the formation of tumors in the pancreas or duodenum that cause the stomach to produce excessive amounts of acid.
  • NSAID-Associated Ulcers: The reduction of risk for stomach ulcers in individuals who require continuous treatment with nonsteroidal anti-inflammatory drugs.

Pharmacological Properties

Lansoprazole is typically formulated to be acid-labile, meaning it is designed to pass through the stomach and be absorbed in the small intestine. Once absorbed, it travels through the bloodstream to reach the gastric parietal cells. The reduction in acid secretion begins shortly after intake, though the full effect on the digestive environment may take several days of consistent use to be established.

What side effects are possible with Lansoprazol?

Officially Documented Adverse Reactions and Safety Profile

The safety profile of Lansoprazol is officially documented by government regulatory agencies, with adverse reactions categorized by their estimated frequency of occurrence and the affected System Organ Class (SOC). The information distinguishes between frequently observed events and rare, clinically significant reactions.


Frequency Classification of Adverse Reactions

Classification Example Adverse Reactions (SOC)
Common (1/100 to <1/10) Diarrhea, Headache, Abdominal pain, Nausea, Vomiting, Dizziness, Flatulence (Gastrointestinal, Nervous System)
Uncommon (1/1,000 to <1/100) Leukopenia, Thrombocytopenia (Blood), Depression (Psychiatric), Arthralgia, Myalgia (Musculoskeletal)
Rare/Very Rare (<1/1,000) Anaphylactic shock, Interstitial nephritis (Renal), Agranulocytosis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) (Immune, Skin)

Serious Safety Considerations and Contextual Patterns

Regulatory documentation highlights serious adverse reactions such as anaphylaxis, interstitial nephritis, and severe blood disorders like pancytopenia and agranulocytosis. These are explicitly documented as rare events.

Specific duration-related safety patterns are noted. Long-term use, typically defined as one year or longer, is associated with an increased risk of fractures of the hip, wrist, or spine. This duration is also linked to the development of fundic gland polyps and hypomagnesemia.

Safety notes also address special populations. The systemic exposure (AUC) of Lansoprazol is documented as being increased in older adults and individuals with hepatic impairment due to reduced clearance. The drug is strictly contraindicated in individuals with a known history of hypersensitivity to Lansoprazol or any substituted benzimidazole.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations of Lansoprazol overdose and the emergency actions mandated by regulatory authorities. Acute overdose reports are rare, and resulting outcomes are generally classified as not severe in documented cases.


Documented Manifestations and Actions

Property Regulatory Statement
Overdose Presentations Overdose may present with symptoms consistent with known adverse reactions or observations of non-specific abnormal blood work.
Physiological Signs Documented signs include transient central nervous system (CNS) symptoms, mild hypertension, and peripheral vasodilation.
Immediate Action Required Immediate medical attention must be sought. Contacting a Poison Control Center or emergency medical services is a required action.
Antidote Status No specific antidote is known.
Supportive Management Management is primarily symptomatic and supportive treatment. Procedures such as gastric lavage and activated charcoal may be considered if performed early. Hemodialysis is not expected to be effective.
Monitoring Hospital observation and monitoring may be required following significant exposure.

Connection to the Overall Overdose Profile

The official regulatory profile confirms that while Lansoprazol overdose is generally not severe, the potential for transient adverse effects necessitates defined emergency procedures. Since no specific antidote is known, the required course of action is to immediately seek professional medical help for supportive management, potential procedural intervention, and observation.

Therapeutic Uses of Lansoprazol

Quick Facts: Lansoprazol Use

Condition
Short-term treatment of active duodenal ulcers
Short-term treatment of active benign gastric ulcers
Healing and maintenance of erosive esophagitis (EE)
Symptomatic gastroesophageal reflux disease (GERD)
Reduction of risk for NSAID-associated gastric ulcers
Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome
Used with antibiotics for the management of H. pylori infection

Lansoprazol is a medication approved to manage conditions associated with excessive stomach acid production. It is indicated for the short-term treatment of symptomatic gastroesophageal reflux disease (GERD), which helps to support patient comfort. The drug is also used to facilitate the healing and maintenance of healing for erosive esophagitis, a condition that involves damage to the lining of the esophagus.

In addition, lansoprazol is used in the management of ulcers. This includes the short-term treatment of active benign gastric ulcers and duodenal ulcers. It is further indicated for use in combination with specific antibiotics for the treatment of H. pylori infection to help reduce the risk of duodenal ulcer recurrence. The medication can also be used to reduce the risk of gastric ulcers in individuals requiring long-term nonsteroidal anti-inflammatory drug (NSAID) therapy, and for the long-term management of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Lansoprazole eligibility is strictly governed by official regulatory standards across defined population domains. The medicine is absolutely contraindicated for any patient with a known severe hypersensitivity to lansoprazole or its excipients. It must also not be used by individuals receiving rilpivirine-containing products, as this combination is explicitly prohibited due to the risk of drug-drug interaction.

Regarding age, the drug is approved for use in adults and for specific conditions in children and adolescents down to one year of age. Use is not recommended for the treatment of symptomatic gastroesophageal reflux disease in infants between one month and one year old, as its efficacy has not been established in this age group. No routine dose adjustment is typically required for older adults or those with renal impairment.

For patients with severe hepatic dysfunction (liver disease), treatment requires specific caution, and some regulatory authorities may recommend a restricted dose. Additionally, the orally disintegrating tablet form contains phenylalanine, restricting its use for individuals with phenylketonuria (PKU). Use is not recommended unless clearly needed during pregnancy or breastfeeding. For a gastric ulcer diagnosis, the possibility of malignancy must be excluded before treatment is started.

What should I know about interactions with other medicines?

The interaction profile of Lansoprazol is defined by its effect on gastric pH and its role as a substrate and weak inhibitor of the CYP2C19 and CYP3A4 enzyme systems, according to government regulatory documents.

Interaction Classification Key Interacting Substances (Official Labeling)
Contraindicated/Not Recommended Nelfinavir and Atazanavir (due to significant reduction in exposure)
Exposure Modification Required Methotrexate and Tacrolimus (co-administration may increase plasma levels)
Metabolic/Monitoring Required Warfarin (coumarin anticoagulants), Theophylline, Clopidogrel, Digoxin

Lansoprazol significantly elevates intragastric pH, which directly reduces the absorption and concentration of pH-dependent drugs such as certain antifungal agents ( Ketoconazole, Itraconazole) and the noted HIV protease inhibitors. Conversely, this pH change may increase the exposure of substances like Digoxin.

Other specific restrictions include: Sucralfate must be administered at least mathbf30 minutes after Lansoprazol to prevent reduced Lansoprazol absorption. Herbal products like St. John's Wort may reduce Lansoprazol plasma concentration. Caution is also officially advised for use in patients with mathbfhepatic impairment due to the potential for slower drug clearance, which may intensify CYP-mediated interactions.

Mechanism of Action

Lansoprazol's mechanism initiates with its entry into the highly acidic secretory canaliculus of the gastric parietal cells as a neutral prodrug. The low pH environment triggers the drug's rapid conversion into a reactive sulfonamide intermediate, ensuring its concentration precisely at the site of acid generation. This active form subsequently forms a strong, covalent disulfide bond with specific cysteine residues on the exposed surface of the H^+/K^+ ATPase enzyme (the proton pump) . This binding event establishes irreversible inhibition, physically disabling the terminal molecular mechanism for gastric acid secretion. The permanent inactivation of the proton pumps leads to a marked and prolonged suppression of both basal and stimulated acid output in the stomach. The physiological effect persists because new acid production requires the synthesis and insertion of entirely new enzyme molecules into the cell membrane, maintaining an elevated gastric pH exceeding the drug's elimination half-life.

Dosage and Administration Information

Lansoprazol is administered via the oral route using delayed-release hard gelatin capsules, orally disintegrating tablets (ODT), or prepared oral suspension. The delayed-release formulation requires that the capsules and tablets must be swallowed whole and not be crushed or chewed to preserve the integrity of the enteric-coated granules for proper absorption.

Administration is typically required before a meal to achieve optimal suppression of gastric acid production. For most common uses, such as the healing of erosive esophagitis or gastric ulcers, the drug is used once daily. However, for specific regimens like the eradication of Helicobacter pylori, the standard is 30 mg twice daily in combination with antibiotics.

Standard adult doses generally range from 15 mg to 30 mg once daily for short-term and maintenance therapies. In pathological hypersecretory conditions, treatment may start at 60 mg once daily, with higher daily doses sometimes administered as divided doses. Considerations are also made for specific populations: a dose reduction is necessary in cases of severe hepatic impairment, although adjustment based on age alone is generally not required.

If a dose is missed, it should be taken as soon as remembered, but individuals must not take two doses at one time to compensate. Furthermore, when co-administered with sucralfate, instructions mandate that Lansoprazol be taken at least 30 minutes prior to the sucralfate dose.

Recent Clinical Evidence

Lansoprazol: Recent Clinical Evidence

Overview of Clinical Research

Lansoprazol, a proton pump inhibitor (PPI), has been the subject of extensive clinical research since its introduction. Studies support its primary use in conditions related to excess stomach acid, including the treatment of duodenal and gastric ulcers, erosive esophagitis, gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions such as Zollinger-Ellison syndrome (ZES). Research also evaluates the use of Lansoprazol in combination with antibiotics for the eradication of H. pylori bacteria, a key factor in ulcer recurrence.


Efficacy and Comparative Studies

Clinical trials, including randomized, controlled studies, have explored the efficacy of Lansoprazol across its approved indications. For instance, in subjects with frequent nighttime heartburn due to GERD, studies found that administration of Lansoprazol 15 mg or 30 mg once daily was associated with a significant reduction in the percentage of nights with heartburn compared to a placebo. Other research compares Lansoprazol with newer acid suppressants; these comparative studies aim to confirm non-inferiority or identify differences in healing rates for ulcers, such as gastric or duodenal ulcers, with outcomes generally showing similar efficacy.


Safety Profile and Special Populations

Lansoprazol is generally well-studied for safety, particularly in adults and pediatric patients aged 1 year and older for certain indications like GERD and erosive esophagitis. The most commonly reported side effects include headache and gastrointestinal disturbances. Long-term studies have noted associations between the class of PPIs and potential risks, including bone fractures and Clostridium difficile infection, though these risks require ongoing research. Due to its metabolism, dosage adjustments may be considered for patients with severe liver impairment.

Key Studies & References

  1. Comparative effectiveness of different recommended doses of omeprazole and lansoprazole for gastroesophageal reflux disease
  2. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management - NICE Guideline CG184
  3. Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis
  4. 25 Years of Proton Pump Inhibitors: A Comprehensive Review - Gut and Liver

Frequently Asked Questions (FAQ)

Common questions about Lansoprazol (FAQ)


Q: How quickly does Lansoprazol start working after taking the first dose?

According to official product labeling, while some individuals may begin to feel relief of symptoms within the first 24 hours, the full intended effect may take 1 to 4 days to be achieved. This is because the medicine works by stopping the acid pumps in your stomach from producing new acid.


Q: How long does the effect of one dose of Lansoprazol typically last?

Lansoprazol is a prolonged-action medicine. Regulatory documents confirm the standard regimen is to take the dose once daily, indicating the drug's acid-suppressing effects are intended to last for approximately 24 hours.


Q: What is the maximum amount of time Lansoprazol is typically taken for?

Official guidance for nonprescription (OTC) use limits treatment to a 14-day course. The labeling specifies that the course should not be repeated more frequently than every four months.


Q: What is the meaning of 'maintenance therapy' when discussing Lansoprazol?

When discussing Lansoprazol, maintenance therapy refers to long-term treatment intended to prevent the relapse or recurrence of healed acid-related conditions, such as erosive esophagitis. This type of ongoing treatment allows for sustained management of chronic conditions.


Q: Is Lansoprazol available without a prescription in some countries?

Regulatory labeling confirms that a 15 mg strength of Lansoprazol is available for the treatment of frequent heartburn in certain jurisdictions as a nonprescription medicine. Higher strengths generally remain available by prescription only.


Q: What is the difference between prescription and over-the-counter strengths of Lansoprazol?

Regulatory labeling distinguishes the available strengths. The nonprescription (OTC) strength is typically 15 mg. Prescription-only formulations are available in varying strengths, which commonly include 15 mg, 30 mg, and 60 mg dosages.


Q: Is it true that Lansoprazol can affect nutrient absorption?

Official product safety information indicates that prolonged use of Lansoprazol, typically defined as a year or more, may potentially interfere with the absorption of Vitamin B12 from food. This is a potential effect noted in regulatory documents regarding long-term PPI use.


Q: Can taking Lansoprazol affect lab results for certain tests?

Official consumer information advises patients to notify their physician if they are scheduled for specific blood work, such as a Chromogranin A (CgA) test. This is because acid-reducing medicines can influence the results of certain diagnostic tests.


Q: Does Lansoprazol interact with common over-the-counter pain relievers?

Regulatory documents acknowledge that Lansoprazol is sometimes prescribed specifically to reduce the risk of ulcers in patients taking Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes many common pain relievers. The official documentation mentions the importance of reviewing all medications, prescription or over-the-counter, with a healthcare provider.


Q: What are the official recommendations for stopping Lansoprazol treatment?

Official medical information notes that any change to a prescribed treatment plan, including discontinuation, should be discussed with a healthcare provider.


Q: Is it normal to feel a change in symptoms when stopping Lansoprazol?

Clinical guidance affiliated with regulatory bodies notes that when stopping this class of medicine, some individuals may experience a temporary increase in acid production, known as rebound hypersecretion. This effect may lead to a brief return or increase in gastrointestinal symptoms.


Q: Why does official guidance recommend the lowest effective dose of Lansoprazol?

Clinical guidelines affiliated with regulatory bodies recommend using a Proton Pump Inhibitor at the lowest dose necessary to effectively manage symptoms. This practice is consistent with the general official approach for managing acid-related conditions.


Q: What is the evidence base for using Lansoprazol in patients with Barrett's esophagus?

Regulatory documents, such as those from Health Canada, specifically include an indication for the use of Lansoprazol in the management of reflux esophagitis in patients diagnosed with Barrett's esophagus.


Q: Is it true that taking Lansoprazol long-term requires routine check-ups?

Official guidance advises that if symptoms worsen, fail to improve within a specific time (such as 14 days for nonprescription use), or return quickly, then further investigation by a doctor is needed. This guidance emphasizes the importance of following up with a health professional if symptoms persist or return, especially when considering long-term use.


Q: Can Lansoprazol be used to treat simple everyday heartburn?

Official product information indicates Lansoprazol is used to provide relief from persistent heartburn and symptoms associated with acid indigestion. The indications are focused on persistent or chronic conditions rather than treatment for infrequent heartburn.


Q: Why do some people need to take Lansoprazol for many months?

When used for an extended period, the treatment is often called maintenance therapy. Regulatory-affiliated clinical research indicates that this long-term use is aimed at preventing the relapse or recurrence of healed acid-related conditions, such as erosive esophagitis.


Q: Does Lansoprazol cause changes in bowel movements, like diarrhea or constipation?

Official regulatory documentation lists diarrhea as a common gastrointestinal adverse reaction to Lansoprazol. Information regarding other changes in bowel function is detailed in the official list of adverse reactions.


Q: Is there a specific time of day Lansoprazol is usually recommended to be taken?

Official administration instructions state that Lansoprazol should be taken before a meal to achieve optimal acid suppression. For many common indications, taking the medicine in the morning is typical.


Q: Does Lansoprazol treat the symptoms or the underlying cause of GERD?

Lansoprazol's primary function is to profoundly reduce stomach acid, which directly relieves symptoms like heartburn. However, it is also used in specific treatment regimens, alongside antibiotics, to eradicate the bacterium H. pylori, which is considered an underlying cause of some ulcers.


Q: What are the signs of a serious side effect from Lansoprazol that require attention?

Regulatory documents list rare but serious adverse reactions, such as severe skin reactions (like Stevens-Johnson Syndrome) and anaphylactic shock (a severe allergic reaction). Official information advises that patients seek medical attention if they experience signs of a severe reaction, such as a spreading rash, difficulty breathing, or swelling of the face or throat.


Q: Are there any food or drinks that should be avoided while taking Lansoprazol?

Official drug labeling specifies that some herbal products, such as St. John's Wort, may reduce the effectiveness of Lansoprazol. The use of herbal products should be reviewed with a healthcare provider. The medicine should also be taken before a meal for best results.

How should Lansoprazol be stored and disposed of?

Storage and Disposal Requirements for Lansoprazole

Lansoprazole must be stored at controlled room temperature, specifically between 20 C to 25 C. The medication requires protection from both light and moisture to maintain its stability. It is mandatory to keep Lansoprazole in its original container, ensuring the container is tightly closed and remains dry.

Safety and Disposal

As a crucial safety measure, Lansoprazole must be stored out of the reach and sight of children.

For disposal, unused or expired product should be taken to a medicine take-back program if one is accessible. If not, the medication must be mixed with an unappealing substance, placed in a sealed bag, and discarded in the household trash. It is officially instructed not to flush Lansoprazole down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lansoprazol found in:

A-Z Index: